Long wait for pivotal data on Sanofi’s oral SERD ends in failurenews2022-03-14T11:25:57+00:00March 14th, 2022|FierceBiotech|
BridgeBio plots path to market for muscular dystrophy drug after posting phase 2 datanews2022-03-14T10:33:35+00:00March 14th, 2022|FierceBiotech|
Nutcracker snags $167M series C to develop ‘push-button’ RNA manufacturing, signs on former Gilead CFOnews2022-03-11T18:13:44+00:00March 11th, 2022|FierceBiotech|
Concert tunes pipeline by selling off CNS assets to startup Terran Biosciencesnews2022-03-11T15:46:21+00:00March 11th, 2022|FierceBiotech|
Immunome’s COVID-19 antibody cocktail back on track for phase 1 after FDA lifts holdnews2022-03-11T14:34:07+00:00March 11th, 2022|FierceBiotech|
AbbVie doubles down on Gedeon Richter pact that brought Vraylar to the worldnews2022-03-11T13:56:40+00:00March 11th, 2022|FierceBiotech|
Histogen seeks to tear up COVID-19 R&D pact and go solo, accuses Amerimmune of failing to push on into phase 2news2022-03-11T11:31:13+00:00March 11th, 2022|FierceBiotech|
Harpoon drug sunk by modest activity, challenging tolerability, forcing pivot from prostate cancer prospectnews2022-03-11T08:54:43+00:00March 11th, 2022|FierceBiotech|
Orphazyme on last leg as court-mediated restructuring drives another wave of layoffsnews2022-03-10T23:31:28+00:00March 10th, 2022|FierceBiotech|
Chutes & Ladders—Janssen’s US oncology lead jumps to Teon as CEOnews2022-03-10T20:40:25+00:00March 10th, 2022|FierceBiotech|
